Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT07072351

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

A Phase Ib/II Study of Hypofractionated Radiotherapy Combined With Immunochemotherapy as Conversion Therapy for Locally Advanced Gastroesophageal Junction Adenocarcinoma

Sponsor: West China Hospital

Conditions Chemotherapy Gastroesophageal Junction Adenocarcinoma Hypofractionated Radiotherapy Immunotherapy

Interventions PD-1 inhibitor SOX Chemotherapy hypofractionated radiotherapy

Updated 2 times since 2025 Last updated: Nov 23, 2025 Started: Sep 15, 2025 Primary completion: May 14, 2028 Completion: May 14, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Chemotherapy and Gastroesophageal Junction Adenocarcinoma, this trial is actively recruiting participants. The trial is conducted by West China Hospital and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Dec 2025 — Present [monthly]

Recruiting PHASE1/PHASE2

Status: Not Yet Recruiting → Recruiting
Aug 2025 — Dec 2025 [monthly]

Not Yet Recruiting PHASE1/PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

West China Hospital

Data source: West China Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Chengdu, China
• Xiamen, China